SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN): INTERIM RESULTS OF THE PROTECT STUDY

Back

Abstract Number

WCN23-1087

Categories

Chronic Kidney Disease, Hypertension, Diabetes and CVD

Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD

Chronic Kidney Disease Diagnosis, Classification and Progression

Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy

Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care

Topic - Special Covid-19

Topic - Education

Abstract Title

SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN): INTERIM RESULTS OF THE PROTECT STUDY

Co-authors

Wong, M.G.(1)*;Heerspink, H.J.(2,3);Komers, R.(4);Mercer, A.(5);Radhakrishnan , J.(6);

ie:	Azwin Z.1, Siti Y.1, John D.2

Institution

(1)University Of Sydney, Renal Medicine- Concord Repatriate General Hospital, Concord, Australia;(2)Concord Repatriation General Hospital, Department Of Renal Medicine, Concord, Australia;(3)University Medical Center Groningen- University Of Groningen, Department Of Clinical Pharmacy And Pharmacology, Groningen, Netherlands;(4)Travere Therapeutics- Inc., Nephrology, San Diego, United States;(5)Jamco Pharma Consulting, Clinical Drug Development, Stockholm, Sweden;(6)Columbia University, Division Of Nephrology, New York, United States;

E-Poster

https://storage.unitedwebnetwork.com/files/1041/79957791d998d445280f29e975c4e9c0.pdf

Audio File

if any